EUVIMEDEUVIMED entdecken
Open Access

Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung

Saraswati Pokhare, Umesh C Sharma, Kristopher Attwood, Sharmeen Mansoor

Journal of Cancer Science and Clinical Therapeutics · 2022 · 06 (03)

DOI: 10.26502/jcsct.5079169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Science and Clinical Therapeutics, 2022. Verfasst von Saraswati Pokhare und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Squamous cell carcinoma of lung is an aggressive disease with a poor a prognosis. While majority of these patients do not survive longer than five years, a minor proportion of patients go on to live longer without disease progression. Identification of biomarkers using easily available immunohistochemical assays could improve risk-stratification in lung cancer patients. Galectin-3, a lectin binding protein, expression has been linked to cancer progression and metastasis. We examined the prognostic impact of tumoral galectin-3 expression in 236 patients with completely resected squamous cell carcinoma of the lung and matching normal tissue using tissue microarray samples. In normal lung, galectin-3 staining is present in alveolar macrophages. Galectin-3 expression is detected in 87% of lung squamous cell carcinoma with a mean galectin-3 score of 2 (range 0-3). There was a significant association between galectin-3 expression and pathological stage (p=0.012) and nodal metastasis (p= 0.013). Galectin-3 expression level, however, was not associated with survival outcome. In conclusion, galectin-3 is expression is seen in alveolar macrophages and close to 90% of lung squamous cell carcinoma. Galectin-3 expression is not associated with survival outcome in North American cohort.

Schlagwörter

Stichwörter der Autor:innen

Galectin-3LungPrognosisSquamous cell carcinomanon-small cell lung cancer

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Medicine, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA.
  • Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Pokhare, S., Sharma, U. C., Attwood, K., & Mansoor, S. (2022). Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung. Journal of Cancer Science and Clinical Therapeutics, 06(03). https://doi.org/10.26502/jcsct.5079169

Vancouver

Pokhare S, Sharma UC, Attwood K, Mansoor S. Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung. Journal of Cancer Science and Clinical Therapeutics. 2022;06(03). doi:10.26502/jcsct.5079169

BibTeX
@article{Pokhare2022,
  author = {Pokhare, Saraswati and Sharma, Umesh C and Attwood, Kristopher and Mansoor, Sharmeen},
  title = {Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung},
  journal = {Journal of Cancer Science and Clinical Therapeutics},
  year = {2022},
  volume = {06},
  number = {03},
  doi = {10.26502/jcsct.5079169}
}
Kostenlos starten →